HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald Trump’s inauguration on 20 January.

The Senate hearing for FDA Commissioner nominee Marty Makary comes after President Trump's NIH pick, Jay Bhattacharya, was ...

A federal pharmaceutical testing facility in St. Louis will remain open, despite appearing on DOGE’s list of scheduled office ...

The user fee program framework includes trigger rates that must be met in order for the FDA to access the funding. Without enough staff at the CDER, which receives user fees, the FDA could find ...

Per the FDA: The DRMB is a cross-CDER governance board responsible for three key objectives: (1) facilitating and coordinating decisions around major product safety issues, (2) providing clear and ...

Marty Makary, likely FDA commissioner under President Trump, appeared before Congress this week as the agency he’s set to lead continues to be rocked by sweeping changes and about-faces.

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its regulatory ...

Trump has made major cuts across several federal health agencies—including the FDA—in the name of government efficiency, resulting in thousands of layoffs. After taking the top spot at CDER ...

Patrizia Cavazzoni was formerly director of the FDA’s Center for Drug Evaluation and Research (CDER) from 2020 until January, when she resigned just ahead of President Trump’s return to office.

MATTB provides assistance and training through outreach to industry. A: CDER's Division of Drug Information (DDI) serves as a focal point for public inquiries regarding human drug products.